According to Zhitong Finance App News, Kanglong Chemical (03759) announced that in order to make full use of the investment and judgment capabilities of professional investment institutions in the biomedical industry, Pharmaron UK Limited (hereinafter referred to as “Kanglong UK”), a wholly-owned subsidiary of the company, plans to participate in the investment of 10 million US dollars in HJ Double Helix Fund L.P., as a limited partner with its own or self-raised funds. On November 6, 2026, Conlon UK signed a fund subscription document according to which the fund's limited partnership rights are subject to the relevant provisions and rights of the fund's “Exempted Limited Partnership of HJ Double Helix Fund L.P.”

The partnership mainly makes equity and equity-related investments in the global biotechnology sector, focusing on nucleic acid drugs, cell and gene therapy, and investment opportunities in their upstream and/or downstream industries.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.